Ranibizumab (10 mg/mL)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Neovascular Age-related Macular Degeneration

Drug Information

Target Indication

Neovascular Age-related Macular Degeneration

Clinical Trial

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Related Pipeline

Obesity

Breast Cancer

Myasthenia Gravis Generalised

Unresectable Hepatocellular Carcinoma

Duchenne Muscular Dystrophy